Limb girdle muscular dystrophy (LGMD) is a group of genetic diseases that cause progressive weakness and wasting in the muscles closest to the center of your body, specifically the shoulders, upper arms, hips, and thighs. It’s the fourth most common type of muscular dystrophy, affecting roughly 1.63 per 100,000 people. More than 30 different genes can cause it, which means “LGMD” is really an umbrella term covering dozens of subtypes that share a similar pattern of muscle loss but differ in severity, speed of progression, and complications.
How LGMD Damages Muscle
Healthy muscles depend on a network of proteins that maintain the structure of muscle fibers, repair the thin membrane surrounding each fiber, and clear out damaged cellular material. In LGMD, a genetic mutation disrupts one of these proteins, and the specific protein affected determines which subtype a person has.
The most common genetic cause involves the CAPN3 gene, which normally produces an enzyme that cuts apart damaged proteins so muscle cells can dispose of them. When this enzyme doesn’t work properly, damaged proteins accumulate inside the cell and gradually impair muscle function. Another common cause involves the DYSF gene, which produces a protein called dysferlin. Dysferlin sits in the membrane that wraps around each muscle fiber and helps patch that membrane when everyday muscle use causes small tears. Without functional dysferlin, those tears go unrepaired, and the fiber slowly breaks down.
A third major category involves the sarcoglycans, a group of four proteins that form a complex anchoring the internal skeleton of a muscle cell to its outer membrane. Mutations in any of the four sarcoglycan genes weaken this anchor, making muscle fibers fragile and prone to damage during contraction. Together, these mechanisms all lead to the same outcome: muscle fibers degenerate faster than the body can replace them, and over time functional muscle tissue is replaced by fat and scar tissue.
How Subtypes Are Classified
LGMD subtypes are organized by their inheritance pattern. Dominant forms, where inheriting one copy of the mutated gene from either parent is enough to cause disease, are labeled with the letter D and numbered 1 through 5. Recessive forms, which require two copies of the mutation (one from each parent), are labeled R and numbered 1 through 23. This naming system was established in 2017, replacing an older system that used “type 1” for dominant and “type 2” for recessive forms. You may still see the older labels (LGMD2A, LGMD2I) in medical records and older literature.
Recessive forms are far more common than dominant ones, and childhood or young adult onset is typical. Among recessive subtypes, LGMDR1 (caused by CAPN3 mutations), LGMDR2 (dysferlin), LGMDR3 through R6 (sarcoglycans), and LGMDR9 (caused by FKRP gene mutations) account for the majority of diagnosed cases. The disease affects men and women at similar rates overall, though men may show earlier onset and faster progression in some subtypes.
Early Symptoms and Progression
About two thirds of people with LGMD first notice symptoms between ages 8 and 15, though onset can range from as young as 2 to as late as 40. Some subtypes present later, typically between 15 and 35, and rare cases have been documented after age 70. The wide variation in timing is one reason diagnosis is often delayed.
The hips and thighs are almost always affected first. Early signs include difficulty climbing stairs, trouble getting up from a chair or the floor, and a wide-based, swaying gait caused by weakness in the gluteal muscles and hip adductors. Weakness in the abdominal muscles contributes to an exaggerated inward curve of the lower back (lordosis) that becomes more noticeable as the disease progresses. The shoulders and upper arms typically weaken later, making it harder to lift objects overhead or carry things at arm’s length. The speed of this progression varies enormously. Some people lose the ability to walk independently within a decade of onset, while others retain mobility well into middle age.
Cardiac and Respiratory Risks
LGMD is not purely a limb disease. Certain subtypes carry significant risk to the heart and lungs, and this is one of the most important things to understand about the condition.
In the sarcoglycan-related subtypes (particularly LGMDR5, formerly 2C), studies have found that roughly 38% of patients develop reduced heart pumping function, with 30% showing clear systolic dysfunction. LGMDR5 patients tend to have more severe cardiac involvement than those with LGMDR6 (formerly 2D). Respiratory complications are equally serious. In one long-term study of these subtypes, 38% of patients experienced significant respiratory events over a median follow-up of six years, and severe restrictive lung disease was common at baseline. Not all subtypes carry the same level of cardiac or respiratory risk, which is why knowing your specific genetic diagnosis matters for long-term monitoring.
How LGMD Is Diagnosed
Diagnosis starts with blood work measuring creatine kinase (CK), an enzyme that leaks out of damaged muscle cells into the bloodstream. In LGMD, CK levels are consistently elevated, often dramatically. Patients with LGMDR1 typically show CK levels around 6,465 U/L, and those with LGMDR2 around 5,912 U/L. Normal CK is generally under 200 U/L. Notably, about a third of patients in one study had elevated CK as their only finding, with no symptoms yet.
While muscle biopsy can reveal characteristic signs of dystrophy, including abnormal fiber sizes, splitting, and replacement of muscle with fibrous tissue, genetic testing has become the primary diagnostic tool. Next-generation sequencing panels can screen all known LGMD-associated genes simultaneously and are now recommended as the first step in the diagnostic process, even for patients who have already had a biopsy. A confirmed genetic diagnosis is important because it identifies the specific subtype, which determines the expected pattern of progression, the risk of heart and lung involvement, and eligibility for subtype-specific clinical trials.
For a condition to formally qualify as LGMD under current criteria, it must involve proximal muscle weakness, a confirmed genetic cause, elevated CK, degenerative changes visible on muscle MRI, dystrophic changes on biopsy, and it must occur in at least two unrelated families.
Managing the Condition
There is no cure for LGMD, and no medication stops or reverses the underlying muscle degeneration. Management focuses on preserving mobility, preventing complications, and maintaining quality of life for as long as possible.
Regular physical and occupational therapy assessments are a cornerstone of care. Therapists can prescribe bracing and assistive devices tailored to your specific weaknesses and contractures. Gentle, low-impact aerobic exercise like swimming or stationary cycling is considered safe and can improve cardiovascular fitness, increase muscle efficiency, and reduce fatigue. Supervised submaximal strength training is also likely safe, but high-intensity or exhaustive exercise should be avoided. Warning signs that you’ve overdone it include feeling weaker (not stronger) within 30 minutes of exercising, excessive soreness lasting 24 to 48 hours, severe cramping, a heavy feeling in the limbs, or prolonged shortness of breath.
Because of the potential for cardiac and respiratory complications, periodic monitoring by a cardiologist and pulmonologist is standard for most subtypes. As respiratory muscles weaken, some people eventually need nighttime ventilatory support. Multidisciplinary clinics that combine neurology, cardiology, pulmonology, orthopedics, genetics, and rehabilitation therapy under one roof offer the most efficient model for ongoing care.
Gene Therapy on the Horizon
The most promising experimental approach for LGMD is gene replacement therapy, which uses a harmless viral vector to deliver a working copy of the defective gene directly into muscle cells. One active Phase 1 clinical trial is testing ATA-100, an intravenous therapy that uses an adeno-associated virus to carry a functional copy of the FKRP gene into patients with LGMDR9. The trial is evaluating safety and tolerability over a five-year follow-up period. Similar gene therapy programs are in development for other subtypes, though most remain in early stages. Because each LGMD subtype involves a different gene, therapies must be developed one subtype at a time, which makes the confirmed genetic diagnosis especially valuable for patients hoping to participate in trials.